Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

41. Manual lymph drainage may not have a preventive effect on the development of breast cancer-related lymphoedema in the long term: a randomised trial

Manual lymph drainage may not have a preventive effect on the development of breast cancer-related lymphoedema in the long term: a randomised trial 30241913 2018 09 30 1836-9561 64 4 2018 Oct Journal of physiotherapy J Physiother Manual lymph drainage may not have a preventive effect on the development of breast cancer-related lymphoedema in the long term: a randomised trial. 245-254 S1836-9553(18)30118-8 10.1016/j.jphys.2018.08.007 What are the short-term and long-term preventive effects (...) of manual lymph drainage (MLD), when used in addition to information and exercise therapy, on the development of lymphoedema after axillary dissection for breast cancer? Randomised controlled trial with concealed allocation, blinded assessors and intention-to-treat analysis. Adults undergoing unilateral dissection for breast cancer were recruited, with 79 allocated to the experimental group and 81 to the control group. The experimental group received guidelines about prevention of lymphoedema, exercise

EvidenceUpdates2018

42. Androgen receptor expression in normal breast tissue and subsequent breast cancer risk

Androgen receptor expression in normal breast tissue and subsequent breast cancer risk 30276234 2018 11 29 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Androgen receptor expression in normal breast tissue and subsequent breast cancer risk. 33 10.1038/s41523-018-0085-3 Sex steroid hormone signaling is critical in the development of breast cancers, although the role of the androgen receptor remains unclear. This study evaluated androgen receptor (AR) expression in normal breast tissue (...) as a potential marker of breast cancer risk. We conducted a nested case-control study of women with benign breast disease (BBD) within the Nurses' Health Studies. Epithelial AR expression was assessed by immunohistochemistry in normal tissue from the BBD biopsy and the percent of positive nuclei was estimated in ordinal categories of 10% for 78 breast cancer cases and 276 controls. Logistic regression models adjusting for the matching factors and BBD lesion type were used to calculate odds ratios (ORs

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

43. Validation of CPS+EG, Neo‐Bioscore, and modified Neo‐Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China

Validation of CPS+EG, Neo‐Bioscore, and modified Neo‐Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China 30296013 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Validation of CPS+EG, Neo-Bioscore, and modified Neo-Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China. 1565-1572 10.1111/1759 (...) -7714.12852 Prognostic assessment after preoperative systemic therapy (PST) is critical to develop a therapeutic strategy for breast cancer management. Currently, a clinical-pathologic staging system that incorporates ER status and nuclear grading (CPS + EG), and the Neo-Bioscore system that includes HER2 status into CPS + EG, are used to predict outcomes in patients with breast cancer after PST. While HER2-positive is recognized as a favorable factor in the Neo-Bioscore system based on results

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

44. Survival estimates stratified by the Nottingham Prognostic Index for early breast cancer: a systematic review and meta-analysis of observational studies.

Survival estimates stratified by the Nottingham Prognostic Index for early breast cancer: a systematic review and meta-analysis of observational studies. BACKGROUND: Estimates of survival for women diagnosed with early staged breast cancer are available based on stratification into prognostic categories defined using the Nottingham Prognostic Index (NPI). This review aimed to identify and summarize the estimated survival statistics from separate sources in the literature and to explore (...) the extent of between-study heterogeneity in survival estimates. METHODS: Observational studies in women diagnosed with early and locally advanced breast cancer reporting overall survival by NPI category were identified using a systematic literature search. An exploratory meta-analysis was conducted to describe survival estimates and assess between-study heterogeneity. RESULTS: Twenty-eight studies were identified. Nineteen studies with sufficient data on overall survival were included in meta-analysis

Systematic Reviews2018 Full Text: Link to full Text with Trip Pro

45. Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer

Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer 30199306 2018 12 07 2378-9506 4 2018 Aug Journal of global oncology J Glob Oncol Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer. 1-9 10.1200/JGO.18.00066 Purpose Over the past three decades, the incidence rate of breast cancer (BC) among Arab women has continually increased. However, data on the prevalence of BRCA1/2 mutations are scarce. Although the population (...) in Saudi Arabia is at large homogeneous and consanguinity is common, especially in the central, eastern, and southern regions of the country, the prevalence of BRCA1 and BRCA2 mutations and the characteristics of BC are not well studied in the country. Methods This prospective observational study intended to determine the prevalence of BRCA1 and BRCA2 mutations and sought to examine the clinicopathologic features of BC associated with these mutations. Results Of 310 patients, 270 (87%) had no mutation

Journal of global oncology2018 Full Text: Link to full Text with Trip Pro

46. Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer

Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer 30211312 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. 31 10.1038/s41523-018-0083-5 Detection of disseminated tumor cells (DTCs) in bone marrow is an established negative prognostic factor. We isolated small pools (...) of (~20) EPCAM-positive DTCs from early breast cancer patients for genomic profiling. Genome-wide copy number profiles of DTC pools ( n = 45) appeared less aberrant than the corresponding primary tumors (PT, n = 16). PIK3CA mutations were detected in 26% of DTC pools ( n = 53), none of them were shared with matched PTs. Expression profiling of DTC pools ( n = 30) confirmed the upregulation of EPCAM expression and certain oncogenes (e.g., MYC and CCNE1 ), as well as the absence of hematopoietic

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

47. Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens

Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens 30211313 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens. 32 10.1038/s41523-018-0084-4 In this pilot study, we introduce a machine learning framework to identify relationships between cancer tissue morphology and hormone receptor pathway activation in breast (...) . 0000000419368710 grid.47100.32 Agus David B DB 0000-0002-7499-7822 1Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, 2250 Alcazar Street, CSC 240, Los Angeles, CA 90089-9075 USA. 0000 0001 2156 6853 grid.42505.36 eng Journal Article 2018 09 04 United States NPJ Breast Cancer 101674891 2374-4677 The authors declare no competing interests. 2018 05 09 2018 08 07 2018 08 10 2018 9 14 6 0 2018 9 14 6 0 2018 9 14 6 1 epublish 30211313 10.1038/s41523-018-0084-4 84

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

48. Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype

Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype 30182055 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype. 30 10.1038/s41523-018-0079-1 RNA-based, multi-gene molecular assays are available and widely used for patients with ER-positive/HER2-negative breast cancers. However, RNA-based genomic (...) tests can be costly and are not available in many countries. Methods for inferring molecular subtype from histologic images may identify patients most likely to benefit from further genomic testing. To identify patients who could benefit from molecular testing based on H&E stained histologic images, we developed an image analysis approach using deep learning. A training set of 571 breast tumors was used to create image-based classifiers for tumor grade, ER status, PAM50 intrinsic subtype, histologic

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

49. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial

Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial 29880292 2018 08 07 1474-5488 19 7 2018 Jul The Lancet. Oncology Lancet Oncol. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. 987-998 S1470-2045(18)30241-9 10.1016/S1470-2045(18)30241-9 ABP 980 (Amgen (...) Inc, Thousand Oaks, CA, USA) is a biosimilar of trastuzumab, with analytical, functional, and pharmacokinetic similarities. We compared the clinical safety and efficacy of ABP 980 with that of trastuzumab in women with HER2-positive early breast cancer. We did a randomised, multicentre, double-blind, active-controlled equivalence trial at 97 study centres in 20 countries, mainly in Europe and South America. Eligible women were aged 18 years or older, had histologically confirmed HER2-positive

EvidenceUpdates2018

50. Impact of Micrometastatic Axillary Nodes on Survival of Breast Cancer Patients with Tumors </=2 cm

Impact of Micrometastatic Axillary Nodes on Survival of Breast Cancer Patients with Tumors Breast Cancer Patients with Tumors ≤2 cm. 10.1007/s00268-018-4725-4 This study investigated the impact of pN1mi disease on the survival of T1 breast cancer patients and examined the clinical usefulness of the online PREDICT tool and updated staging system (...) . The node stages of 2344 patients were divided into pN0, pN1mi, and pN1a. Clinicopathological parameters and survival outcomes were retrospectively analyzed. Data for 111 micrometastatic diseases were applied to the PREDICT version 2.0 and re-classified using the 8th edition of the cancer staging manual. Univariable analyses demonstrated worse disease-free and overall survival rates for patients with node-positive cancer; however, the significance was not maintained in multivariable analyses

EvidenceUpdates2018

51. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 29860922 2018 08 15 1527-7755 36 24 2018 Aug 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer (...) : MONALEESA-3. 2465-2472 10.1200/JCO.2018.78.9909 Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy in the advanced setting. Patients and Methods Patients were randomly assigned at a two-to-one ratio to ribociclib plus fulvestrant or placebo plus fulvestrant. The primary end point was locally

EvidenceUpdates2018

52. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial 29804902 2018 08 07 1474-5488 19 7 2018 Jul The Lancet. Oncology Lancet Oncol. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. 904-915 S1470-2045(18)30292-4 10.1016/S1470-2045(18)30292-4 In MONALEESA-2, ribociclib plus letrozole showed (...) improved progression-free survival compared with letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer. MONALEESA-7 aimed to assess the efficacy and safety of ribociclib plus endocrine therapy in premenopausal women with advanced, HR-positive breast cancer. This phase 3, randomised, double-blind, placebo-controlled trial was done at 188 centres in 30 countries. Eligible patients were premenopausal women aged 18-59

EvidenceUpdates2018

53. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)

Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103) 30040523 2018 09 13 1527-7755 36 25 2018 Sep 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast (...) Cancer (E5103). 2621-2629 10.1200/JCO.2018.79.2028 Purpose Bevacizumab improves progression-free survival but not overall survival in patients with metastatic breast cancer. E5103 tested the effect of bevacizumab in the adjuvant setting in patients with human epidermal growth factor receptor 2-negative disease. Patients and Methods Patients were assigned 1:2:2 to receive placebo with doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (arm A), bevacizumab only during AC and paclitaxel

EvidenceUpdates2018

54. Neratinib (Nerlynx) - Breast cancer, breast neoplasms

Neratinib (Nerlynx) - Breast cancer, breast neoplasms 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 13 July 2018 EMA/CHMP/525204/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Nerlynx International (...) disease-free survival DFS-DCIS disease-free survival including ductal carcinoma in situ ECG electrocardiogram ECOG Eastern Cooperative Oncology Group EGFR epidermal growth factor receptor EQ-5D EuroQol 5-Dimension Questionnaire ER estrogen receptor ERBB erythroblastic leukemia viral oncogene homolog; also termed HER ExteNET Extended Adjuvant Treatment of Breast Cancer with Neratinib FACT-B Functional Assessment of Cancer Therapy-Breast FMO flavin-containing monooxygenase GI gastrointestinal HER human

European Medicines Agency - EPARs2018

55. AlignRT in breast cancer radiotherapy

AlignRT in breast cancer radiotherapy AlignR AlignRT in breast cancer r T in breast cancer radiother adiotherap apy y Medtech innovation briefing Published: 24 August 2018 nice.org.uk/guidance/mib157 pathways Summary Summary The technology technology described in this briefing is the AlignRT patient position monitoring system. This briefing focuses on its use during breast cancer radiation therapy. The inno innovativ vative aspect e aspect is that it may avoid inaccurate treatment by precisely (...) in this briefing are from 4 observational studies involving a total of 228 adults in tertiary care settings in the US and Europe. They suggest that AlignRT is effective in maintaining accurate patient positioning during breast cancer radiotherapy. K Ke ey uncertainties y uncertainties are that there is no evidence from direct comparisons of AlignRT with location monitoring or from studies specifically using AlignRT as the main intervention. The cost cost of AlignRT is £150,000 to £225,000 per unit (excluding

National Institute for Health and Clinical Excellence - Advice2018

56. Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy

Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy 30233820 2018 11 14 2059-7029 3 6 2018 ESMO open ESMO Open Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy. e000305 10.1136/esmoopen-2017-000305 Tumour-infiltrating lymphocytes (TILs) can be used to monitor the immune tumour microenvironment (iTME) and predict (...) treatment response and outcome in breast cancer. We evaluated the prognostic significance of the levels of CD8 + TILs and forkhead box protein (FOXP3)-positive TILs before and after neoadjuvant chemotherapy (NAC). We examined 136 patients with breast cancer treated with NAC. The number of CD8 + TILs and FOXP3 + TILs in biopsy specimens and residual tumours was evaluated by immunohistochemistry. Patients with a high rate of change in the CD8/FOXP3 ratio (CFR) had significantly better recurrence-free

ESMO open2018 Full Text: Link to full Text with Trip Pro

57. NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer

NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer 30182054 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer. 29 10.1038/s41523-018-0080-8 The key negative regulatory gene of the RAS pathway, NF1 , is mutated or deleted in numerous cancer types and is associated with increased cancer risk and drug resistance. Even though women (...) with neurofibromatosis (germline NF1 mutations) have a substantially increased breast cancer risk at a young age and NF1 is commonly mutated in sporadic breast cancers, we have a limited understanding of the role of NF1 in breast cancer. We utilized CRISPR-Cas9 gene editing to create Nf1 rat models to evaluate the effect of Nf1 deficiency on tumorigenesis. The resulting Nf1 indels induced highly penetrant, aggressive mammary adenocarcinomas that express estrogen receptor (ER) and progesterone receptor (PR). We

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

58. Knowledge, Beliefs, and Attitudes About Breast Cancer Screening in Latin America and the Caribbean: An In-Depth Narrative Review

Knowledge, Beliefs, and Attitudes About Breast Cancer Screening in Latin America and the Caribbean: An In-Depth Narrative Review 30156947 2018 12 07 2378-9506 4 2018 Aug Journal of global oncology J Glob Oncol Knowledge, Beliefs, and Attitudes About Breast Cancer Screening in Latin America and the Caribbean: An In-Depth Narrative Review. 1-25 10.1200/JGO.18.00053 Purpose Breast cancer (BCA) is the most common cancer and leading cause of cancer mortality among women in Latin America (...) , this is the first literature review to include articles from all countries and national languages (Portuguese, English, and Spanish) that pertain to this topic. Methods OVID Medline, CINAHL, and Web of Science/SciELO were used to identify articles. Thirty-five articles were included according to inclusion and exclusion criteria. Results Themes identified in the literature included knowledge about screening procedures and cause of cancer; knowledge sources; catalysts and deterrents for screening, such as family

Journal of global oncology2018 Full Text: Link to full Text with Trip Pro

59. Sentinel lymph node B cells can predict disease-free survival in breast cancer patients

Sentinel lymph node B cells can predict disease-free survival in breast cancer patients 30155518 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Sentinel lymph node B cells can predict disease-free survival in breast cancer patients. 28 10.1038/s41523-018-0081-7 Tumor invasion into draining lymph nodes, especially sentinel lymph nodes (SLNs), is a key determinant of prognosis and treatment in breast cancer as part of the TNM staging system. Using multicolor histology (...) and quantitative image analysis, we quantified immune cells within SLNs from a discovery cohort of 76 breast cancer patients. We found statistically more in situ CD3 + T cells in tumor negative vs. tumor positive nodes (mean of 8878 vs. 6704, respectively, p = 0.006), but no statistical difference in CD20 + B cells or CD1a + dendritic cells. In univariate analysis, a reduced hazard was seen with a unit increase in log CD3 with HR 0.49 (95% CI 0.30-0.80) and log CD20 with HR 0.37 (95% CI 0.22-0.62

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

60. A survey of current surgical treatment of early stage breast cancer in China

A survey of current surgical treatment of early stage breast cancer in China 30234145 2018 11 14 2331-4737 5 7-8 2018 Jul Oncoscience Oncoscience A survey of current surgical treatment of early stage breast cancer in China. 239-247 10.18632/oncoscience.445 The purpose of this national survey is to explore the patterns of surgical management for early stage breast cancer patients in China. A paper questionnaire survey was sent to the representatives from 520 hospitals who attended (...) an international symposium in Guangzhou, China, 2014. The questionnaire included demographic information, initials and most preferred approaches for breast cancer surgery. The results were presented descriptively. The response rate was 42.5%. Only 7% of hospitals with >50% rate of breast conserving surgery (BCS). Intraoperative frozen sections and additional cavity margins assessment were used at 88% and 30.9% of hospitals, respectively. For invasive carcinoma, 15% of participants defined an adequate margin

Oncoscience2018 Full Text: Link to full Text with Trip Pro